In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Strakan, ProSkelia merge in stock swap

Executive Summary

To create a specialty pharmaco with greater R&D capabilities and a larger European sales force, privately held therapeutic development companies Strakan Group Ltd. (bone and skin disease) and ProSkelia SAS (musculoskeletal and hormone disorders) will merge in a stock swap. Each company will hold an equal share in the new entity, which is expected to file for an IPO within a year. Warburg Pincus, which owns over 37% of Strakan, and about 60% of ProSkelia, will have a 50% interest in the combined entity.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register